Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.

Journal of neurology·2023
Same author

Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.

Multiple sclerosis journal - experimental, translational and clinical·2019
Same author

Response to 'Seasonal variation of vitamin D and Epstein-Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'.

European journal of neurology·2018
Same author

The economic impact of multiple sclerosis to the patients and their families in Norway.

The European journal of health economics : HEPAC : health economics in prevention and care·2018
Same author

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

European journal of neurology·2017
Same author

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

European journal of neurology·2016
Same journal

Sleep quality and arousal in migraine and tension-type headache: the headache-sleep study.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Diffusion-weighted lesions in acute ischaemic stroke patients with migraine.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Mild stroke: safety and outcome in patients receiving thrombolysis.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.

Acta neurologica Scandinavica. Supplementum·2014
Same journal

Advances in genetic diagnosis of neurological disorders.

Acta neurologica Scandinavica. Supplementum·2014
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Benign multiple sclerosis: a need for a consensus.

S B Glad1, J H Aarseth, H Nyland

  • 1Department of Neurology, Haukeland University Hospital, The Norwegian Multiple Sclerosis Competence Centre, Bergen, Norway. solveig.bergliot.glad@helse-bergen.no

Acta Neurologica Scandinavica. Supplementum
|July 1, 2010
PubMed
Summary
This summary is machine-generated.

Defining benign multiple sclerosis (MS) impacts its frequency. An Expanded Disability Status Scale (EDSS) score of 2.0 or less best identifies benign MS with fewer non-motor symptoms and lower unemployment.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 11, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

  • Neurology
  • Clinical Research
  • Epidemiology

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease.
  • Defining benign MS is crucial for understanding disease course and patient outcomes.
  • Previous studies have varied in their definitions of benign MS.

Purpose of the Study:

  • To evaluate how different definitions affect the estimated frequency of benign multiple sclerosis (MS).
  • To assess the association between various benign MS definitions and the presence of non-motor symptoms.
  • To examine employment status in relation to different benign MS classifications.

Main Methods:

  • A cohort of 188 patients with MS onset between 1976-1986 in Hordaland County, Norway, were followed up.
  • Clinical examinations included the Expanded Disability Status Scale (EDSS) in 2003.
  • Benign MS was defined using EDSS cut-offs (2.0, 3.0, 4.0) and employment status.

Main Results:

  • Benign MS frequency ranged from 14.5% (EDSS ≤2.0) to 40.8% (EDSS ≤4.0).
  • Using full-time employment as a criterion yielded only 12.3% benign MS.
  • Patients with EDSS ≤2.0 reported fewer non-motor symptoms and lower unemployment.

Conclusions:

  • An EDSS score of 2.0 or less, combined with at least 10 years of disease duration, is proposed as the most suitable criterion for identifying benign MS.
  • This definition is associated with a better patient experience regarding non-motor symptoms and employment.
  • Refining the definition of benign MS is essential for accurate clinical assessment and prognosis.